Biotech companies continue to grow and attract major funding from both public and private sources. In 2020, global venture-capital funding and deals reached their highest ever level of $36.6 billion, while IPOs raised more than twice the amount of capital compared with 2019.
To read the article, see “Can European biotechs achieve greater scale in a fragmented landscape?” June 29, 2021.